Veru Inc. (VERU)

NASDAQ: VERU · IEX Real-Time Price · USD
23.78
+1.53 (6.88%)
At close: Aug 17, 2022 4:00 PM
23.60
-0.18 (-0.76%)
After-hours: Aug 17, 2022 7:10 PM EDT
6.88%
Market Cap 1.91B
Revenue (ttm) 52.41M
Net Income (ttm) -47.05M
Shares Out 80.15M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE 117.65
Dividend n/a
Ex-Dividend Date n/a
Volume 12,378,516
Open 22.15
Previous Close 22.25
Day's Range 22.10 - 24.55
52-Week Range 4.34 - 24.55
Beta -0.40
Analysts Buy
Price Target 35.90 (+51.0%)
Earnings Date Aug 11, 2022

About VERU

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial f... [Read more...]

Industry Personal Products
IPO Date Jul 19, 1990
CEO Mitchell Steiner
Employees 252
Stock Exchange NASDAQ
Ticker Symbol VERU
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VERU stock is "Buy." The 12-month stock price forecast is 35.9, which is an increase of 50.97% from the latest price.

Price Target
$35.9
(50.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

This Growth Stock Has Soared Over 200% Year to Date -- Is It a Buy?

More than two years into the pandemic, hospitalized patients with severe cases may get a game-changing treatment.

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MIAMI, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the ma...

Why Veru Stock Is Flying High Today

Investors eagerly wait authorization of Veru's COVID-19 therapy.

Why Is VERU Stock Up 36% Today?

Source: Shutterstock Veru (NASDAQ: VERU ) stock is heading higher on Thursday as investors celebrate positive news in its earnings report for the fiscal third quarter of 2022. However, it's not the earn...

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regul...

-- Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022-- --The UK's Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabi...

Got $5,000? These 2 Stocks Are Crushing the Market This Year

Can they continue outperforming the S&P?

Other symbols: CVX

Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at Hi...

MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the ma...

7 Small-Cap Growth Stocks With 1,000% Upside Potential

Small-cap growth stocks with 1,000% upside potential is our topic for today. They are usually young companies with a market capitalization (cap) between $300 million and $2 billion.

Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th

MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the ma...

European Medicines Agency's Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospita...

MIAMI, July 27, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the ma...

UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization ...

MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the ma...

Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This Year

Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?

Other symbols: TMDXVRTX

Why Veru Stock Jumped Today

The company is generously paying a few new hires.

Why Veru Stock Soared 15% Higher on Monday

One analyst enthusiastically reiterates his case for buying the stock.

2 Small-Cap Stocks With Large-Cap Potential

They're already raking in revenue, and more is on the way.

Other symbols: SUPN

VERU's Shares Jump on Successful COVID-19 Study Results

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.

Why Veru Stock Got Dented Today

A short-seller published a new analysis that calls some of its clinical trial data into question.

Why Veru Stock Trounced the Market on Thursday

Several analysts reiterate their bullish outlook on the company.

Jefferies Analyst Predicts FDA Emergency Use Nod For Veru's New COVID-19 Therapy In One Month

Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's (NASDAQ: VERU) sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies writes.  ...

VERU Stock Pops on Clinical Trial Update

Veru (VERU) stock is on the move Wednesday after the company published results from its Phase 3 clinical trial of sabizabulin. The post VERU Stock Pops on Clinical Trial Update appeared first on Investo...

Why Veru Stock Is Popping Today

It just published great-looking data from a phase 3 clinical trial for its antiviral treatment for severe COVID-19.

Why Veru Stock Is Soaring

Veru Inc (NASDAQ: VERU) shares are trading higher Wednesday after the company announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabuli...

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating t...

- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints -

Why Veru Stock Surged Today

The biotech's experimental oral COVID-19 treatment could be a game changer.